Invion corrects director shareholding disclosure in ASX filing

An announcement from Invion ( (AU:IVX) ) is now available.

Invion Limited has disclosed that an indirect shareholding of director Alistair Bennallack, held via a superannuation fund, was omitted from earlier director interest notices lodged in 2020 and 2025, and has now filed a corrected Appendix 3Y with the ASX. The company stressed that the omission involved a relatively small parcel of 12,963 shares, did not stem from any on-market transaction, and is considered an isolated administrative error, reinforcing that director interests are regularly reviewed under its governance processes.

The correction is intended to reaffirm Invion’s adherence to ASX Listing Rule 3.19A requirements on director holdings and to maintain transparency with investors and regulators. By promptly updating the market and emphasizing its standing board review of directors’ interests, Invion seeks to limit any potential concerns over compliance lapses and preserve confidence in its corporate governance framework.

More about Invion

Invion Limited is an ASX-listed life-science company focused on developing its Photosoft technology, a next generation photodynamic therapy platform for treating cancers, atherosclerosis and infectious diseases. The company holds global exclusive rights to Photosoft across multiple cancer and non-cancer indications, positioning it within emerging therapies that use non-toxic photosensitisers and light to selectively destroy diseased cells while stimulating immune responses.

YTD Price Performance: -37.63%

Average Trading Volume: 112,558

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$5.62M

For detailed information about IVX stock, go to TipRanks’ Stock Analysis page.